osimertinib
astrazeneca
['nsclc', 'sclc', 'osimertinib']
appreciated showing global prevalence of egfr mutations instead of us centric rates during his #asco23 plenary that conclusively demonstrated osimertinib os superiority in egfr mut nsclc 
@OncoKB Lead Scientist @MSKPathology Assistant Member @sloan_kettering cancer biologist. Mother, wife of @JPayneWrites, daughter & sister. tweets are mine.